Antihypertensive action of bendroflumethiazide: increased prostacyclin production?
A within-patient randomized, double-blind, crossover study was performed to investigate mechanisms of action of bendroflumethiazide in mild essential hypertension. Significant reductions in lying, standing, and postexercise blood pressure were seen after both 3 days and 10 wk treatment with bendroflumethiazide 10 mg daily. Plasma levels of 6-oxo-PGF1 alpha, the chemical hydrolysis product of prostacyclin, were increased by both 3 days and 10 wk therapy with bendroflumethiazide. This raises the possibility that thiazides may reduce peripheral resistance by increasing prostacyclin biosynthesis.
D000328:Adult; D000368:Aged; D001539:Bendroflumethiazide / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D004573:Electrolytes / Q000378:metabolism; D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000494:pharmacology; D011453:Prostaglandins / Q000096:biosynthesis*; D011460:Prostaglandins F / Q000097:blood; D012083:Renin / Q000097:blood; D012964:Sodium / Q000378:metabolism
D004573:Electrolytes; D011453:Prostaglandins; D011460:Prostaglandins F; D001539:Bendroflumethiazide; D012964:Sodium; D011464:Epoprostenol; D012083:Renin; D009638:Norepinephrine